Author: Daniela Muresan1, Septimiu Voidăzan2, Andreea Salcudean3, Cristina Raluca Bodo4, Iosif Gabos Grecu5
Affiliation: <sup>1</sup> Doctoral School of Medicine and Pharmacy, Department of Medicine, 'George Emil Palade' University of Medicine, Pharmacy, Sciences and Technology, 540142 Targu Mures, Romania.
<sup>2</sup> Department of Epidemiology, 'George Emil Palade' University of Medicine, Pharmacy, Sciences and Technology, 540142 Targu Mures, Romania.
<sup>3</sup> Department of Ethics and Social Sciences, 'George Emil Palade' University of Medicine, Pharmacy, Sciences and Technology, 540142 Targu Mures, Romania.
<sup>4</sup> Psychiatric Clinic No. 2, Mures County Hospital, 540142 Targu Mures, Romania.
<sup>5</sup> Senior Psychiatrist Psychiatric Clinic No. 1, 'George Emil Palade' University of Medicine, Pharmacy, Sciences and Technology, 540142 Targu Mures, Romania.
Conference/Journal: Exp Ther Med
Date published: 2022 Apr 1
Other:
Volume ID: 23 , Issue ID: 4 , Pages: 264 , Special Notes: doi: 10.3892/etm.2022.11190. , Word Count: 264
Depression is a negative emotional state that may persist for short or long periods of time with varying severity. The aim of the present study was to evaluate the method by which bioresonance therapy can improve the severity of recurrent depressive disorder with moderate and mild episodes experienced by patients. Bioresonance therapy is a method of energy treatment that processes the electromagnetic information of the human body using a sensitive Mora Nova device using electrodes. In addition, this improvement was compared with the one obtained by applying monotherapy with selective serotonin reuptake inhibitors. The study included two groups of patients suffering from depression. The first group received bioresonance treatment for five weeks. The second group received either newly introduced or on-going pharmacological treatment with selective serotonin reuptake inhibitor antidepressants, as monotherapy, for five weeks. An outcome measurement of severity was performed. Results revealed that, the score improvement on the Hamilton Scale, used for assessing depression and comprising 17 items, showed a mean of 3.1 [standard deviation (SD), 1.28] for the bioresonance group one and a mean of 2.2 (SD, 0.61) for the second group. The difference between the two data series was statistically significant (P<0.0001, Student's t-test). As the bioresonance therapy outcome was higher than the selective serotonin reuptake inhibitor medication outcome, it can be concluded that bioresonance can reduce the severity of the patients facing recurrent depressive disorder with moderate and mild episodes. Furthermore, the reduction in severity for the bioresonance group compared with the antidepressant medication group was statistically significant.
Keywords: alternative medicine; bioresonance therapy; depression; selective serotonin reuptake inhibitors; serotonin.
PMID: 35251330 PMCID: PMC8892610 DOI: 10.3892/etm.2022.11190